| JVP | [POMD P 49 - 52] 1) Jugular Vein Pressure 2) Jugular Venous Pulse ... |
|---|---|
| AIMS | abnormal involuntary movement scale; aid for the impaired medical student; arthritis impact measurem... |
| EI | Edmonton injector; electrolyte imbalance; electron impact; electron ionization; emotionally impaired... |
| EIS | Environmental Impact Statement; Epidemic Intelligence Service |
| SIP | Sickness Impact Profile; slow inhibitory potential; surface inductive plethysmography |
| HIV AN | HIV associated nephropathy |
|---|---|
| HIV- | HIV negative |
| HIV+ | HIV positive |
| HIV Pr | HIV protease |
| HIV- | HIV sero-negative |
| sickness impact profile | A quality-of-life scale developed in the united states in 1972 as a measure of health status or dysfunction generated by a disease. It is a behaviourally based questionnaire for patients and addresses activities such as sleep and rest, mobility, recreation, home management, emotional behaviour, social interaction, and the like. It measures the patient's perceived health status and is sensitive enough to detect changes or differences in health status occurring over time or between groups. (12 Dec 1998) |
|---|---|
| draft environmental impact statement | (DEIS) A draft statement of environmental effects. Section 102 of the National Environmental Policy Act requires a DEIS for all major federal actions. The DEIS is released to the public and other agencies for comment and review. (05 Dec 1998) |
| impact | 1. Contact or impression by touch; collision; forcible contact; force communicated. "The quarrel, by that impact driven." (Southey) 2. <mechanics> The single instantaneous stroke of a body in motion against another either in motion or at rest. Source: Websters Dictionary (01 Mar 1998) |
| impact fusion | <radiobiology> Fusion approach where a fuel projectile is acclerated and impacted into either a stationary target or another projectile. This is valuable for scientific purposes but not a candidate for a fusion energy source because the likelihood of fusion occurring in a single collision is too low. Multiple accelerated pellets colliding with spherical symmetry might be a viable inertial confinement approach. An impact fusion driver accelerates the macroparticles and is used in inertial confinement fusion. (13 Nov 1997) |
| impact resistance | The ability of a lens for eyewear to withstand impact without shattering or breaking, i.e., of a 3/8 -inch steel ball dropped 50 feet; criteria for determination of impact resistance are specified by U.S. Regulations. (05 Mar 2000) |
| environmental impact statement | (EIS; FEIS) A statement of the environmental effects of a proposed action and of alternative actions. Section 102 of the National Environmental Policy Act (NEPA) requires an EIS for all major federal actions. (05 Dec 1998) |
| anti-HIV agents | Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids. (12 Dec 1998) |
| receptors, HIV | Cellular receptors that bind the human immunodeficiency virus that causes aids. Included are CD4 antigens, found on t4 lymphocytes, and monocytes/macrophages, which bind to the HIV envelope protein gp120. (12 Dec 1998) |
| chronic symptomatic HIV infection | This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening. Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc). (27 Sep 1997) |
| middle stage HIV disease | <disease> This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening. Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc). (27 Sep 1997) |
| primary HIV infection | <infectious disease> The flu-like syndrome that oc immediately after a person contracts HIV. This mini infection precedes seroconversion and is characterised fever, sore throat, headache, skin rash and swollen glands. (06 Mar 1998) |
| HIV | <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified. Type 1: the retrovirus recognised as the agent that induces AIDS. Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa. Acronym: HIV (11 Nov 1997) |
| HIV-1 | The type species of lentivirus and widely recognised as the aetiologic agent of acquired immunodeficiency syndrome (aids). It is characterised by its cytopathic effect and affinity for the t4-lymphocyte. (12 Dec 1998) |
| HIV-1 reverse transcriptase | <enzyme> HIV-1 enzyme responsible for the synthesis of DNA from genomic RNA of the virus. It is encoded by the pol gene of HIV-1. Registry number: EC 2.7.7.- (12 Dec 1998) |
| HIV-2 | An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian lentivirus siv and infects only t4-lymphocytes expressing the CD4 phenotypic marker. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|